Insight Molecular Diagnostics R&D Spending Growth & History (IMDX)

Insight Molecular Diagnostics's r&d spending was $15.9M for fiscal 2025.

View full Insight Molecular Diagnostics company overview

Insight Molecular Diagnostics annual r&d spending history

Insight Molecular Diagnostics annual r&d spending

Fiscal yearPeriod endedR&D spendingChangeGrowth
20252025-12-31$15.9M$6.1M+61.60%
20242024-12-31$9.8M$545,000+5.86%
20232023-12-31$9.3M$2.0M+27.30%
20222022-12-31$7.3M$2.3M+45.00%
20212021-12-31$5.0M−$4.8M−48.62%
20202020-12-31$9.8M$3.0M+44.24%
20192019-12-31$6.8M$280,000+4.30%
20182018-12-31$6.5M−$660,000−9.20%
20172017-12-31$7.2M$1.5M+26.37%
20162016-12-31$5.7M$1.1M+25.40%
20152015-12-31$4.5M$565,000+14.26%
20142014-12-31$4.0M

Insight Molecular Diagnostics r&d spending trends

Over the last five fiscal years, Insight Molecular Diagnostics's r&d spending increased from $9.8M to $15.9M, a change of $6.1M. The latest reported quarter, Q2 2026, shows $4.5M.

About the metric

What research and development spending means

Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.

Calculation and source

SEC-reported R&D expense

TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Insight Molecular Diagnostics source filings ↗

Community posts

It’s quiet here.

No posts about IMDX yet. Start the conversation.

Write the first post